News of Note—GlaxoSmithKline’s Mosquirix, Emergent BioSolutions and more

non
In this week's news of note, a pilot study of GSK’s malaria vaccine, Mosquirix, has been delayed. (Pixabay)

Here is some other vaccine news of note for the week:

> Stakeholders are still navigating the complex planning process for a three-country pilot study of GlaxoSmithKline’s Mosquirix. Financial Times article

> Emergent BioSolutions got approval to introduce its anthrax vaccine, BioThrax, in Italy, Poland, the U.K., the Netherlands and France. Washington Business Journal article

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.

> CDC Director Robert Redfield divested stock in Baltimore vaccine company Profectus BioSciences before taking on the CDC job. The Washington Post article